The Effect of Gemfibrozil, Niacin and Cholestyramine Combination Therapy on Metabolic Syndrome in the Armed Forces Regression Study

Abstract Introduction Metabolic syndrome is a powerful predictor of cardiovascular events independent of overt diabetes. Dietary restriction and weight loss modify metabolic syndrome components. This study addresses whether combination pharmacologic therapy focused on dyslipidemia provides additiona...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of the medical sciences 2011-05, Vol.341 (5), p.378-382
Hauptverfasser:	Krasuski, Richard A., MD, Devendra, Ganesh P., BA, Cater, George, BS, MS, Whitney, Edwin J., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anticholesteremic Agents - therapeutic use Biological and medical sciences Body Mass Index Cholestyramine Resin - therapeutic use Diabetes Diabetes. Impaired glucose tolerance Double-Blind Method Drug Therapy, Combination Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Exercise Female Gemfibrozil - therapeutic use General aspects HDL Humans Hypolipidemic Agents - therapeutic use Internal Medicine Life Style Lipids - blood Longitudinal Studies Male Medical sciences Metabolic diseases Metabolic syndrome Metabolic Syndrome - blood Metabolic Syndrome - drug therapy Middle Aged Military Personnel Miscellaneous Niacin - therapeutic use Other metabolic disorders Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!